Last updated on September 2017

Study title: A randomized, double blind, multicenter phase III study of regorafenib in patients with hepatocellular carcinoma (HCC) after sorafenib


Brief description of study

Study title: A randomized, double blind, multicenter phase III study of regorafenib in patients with hepatocellular carcinoma (HCC) after sorafenib

Detailed Study Description

This clinical study evaluates the efficacy and safety of regorafenib in patients with advanced liver cancer who have progressed on sorafenib treatment. Approximately 560 patients who meet the entry criteria will be randomly assigned in a 2:1 ratio to regorafenib or placebo (1/3 chance to receive placebo). Primary endpoint of the study is overall survival.

For Study Locations, Click Here

Clinical Study Identifier: TX153133

Find a site near you

Start Over

Research Center

Located in: Additional Locations, XX Argentina
7.12miles
  Connect »